Last reviewed · How we verify
NCT07085858
Study of the Preventive Effects and Mechanisms of Yeast β-Glucan on Upper Respiratory Tract Infections
NA trial testing yeast β-glucan in Upper Respiratory Tract Infections in 96 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | LanZhou University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 96 |
| Start date | 25 July 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- yeast β-glucan
- placebo
Conditions studied
- Upper Respiratory Tract Infections — all drugs for Upper Respiratory Tract Infections →
Sponsor
LanZhou University
Who can join
Adults 18 to 35, any sex, with Upper Respiratory Tract Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed as a randomized, double-blind, placebo-controlled human intervention trial targeting a population of university students with persistent allergic rhinitis (AR) symptoms. The primary objective is to evaluate the preventive effect and underlying mechanisms of yeast β-glucan on upper respiratory tract infections (URTIs), providing scientific evidence for the prophylactic use of prebiotics in high-risk populations. All participants will be stratified by sex and body mass index (BMI), and then randomly assigned to either the yeast β-glucan group or the control group. During the 15-week study period-including a 1-week run-in phase, a 12-week intervention phase, and a 2-week follow-up phase-participants in the intervention group will take two yeast β-glucan capsules daily after meals, while the control group will take two placebo capsules with identical appearance, taste, and packaging. Participants will be monitored daily for the occurrence of URTIs. In the event of an infection, the Wisconsin Upper Respiratory Symptom Survey (WURSS-24) will be used to assess symptom severity and duration. Medication use, including dosage, frequency, and timing, will also be recorded. Weekly follow-ups will assess changes in Total Nasal Symptom Score (TNSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and adverse events. In addition, participants will undergo comprehensive follow-up assessments at Week 0 and Week 12, including TNSS and RQLQ questionnaires, a 3-day dietary intake survey, anthropometric measurements (e.g., height, weight, body fat percentage), and biological sample collection (blood, urine, and stool samples).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07085858
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of yeast β-glucan
Trials testing the same drug.
- NCT06861062 — Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patie · NA · recruiting
Other recruiting trials for Upper Respiratory Tract Infections
Currently open trials in the same condition.
- NCT06271655 — Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Dep · NA · active not recruiting
Other LanZhou University trials
Trials by the same sponsor.
- NCT07312370 — Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing · Phase 4 · not yet recruiting
- NCT07263867 — Enhanced Ward Rounds for Bowel Preparation Quality in Hospitalized Patients Undergoing Colonoscopy · NA · not yet recruiting
- NCT07314554 — Recurrence After Gastric and Intestinal Polyp Resection · not yet recruiting
- NCT07286877 — Enhanced Ward Rounds and Communication for Pre-procedural Anxiety in GI Endoscopy Patients · NA · not yet recruiting
- NCT07234344 — A Predictive Model for Midwives' C F: A Cross-Sectional Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07085858 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LanZhou University
- Last refreshed: 25 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07085858.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing